RET TKI

Potential role in thyroid cancers

Alessandro Antonelli, Poupak Fallahi, Silvia Martina Ferrari, Caterina Mancusi, Michele Colaci, Libero Santarpia, Clodoveo Ferri

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (RET/PTC) or signaling kinases (vascular endothelial growth factor receptor [VEGFR]) involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies able to inhibit RET (sorafenib, imatinib, vandetanib) in stabilizing the course of the disease. The aim of the introduction of these targeted therapies is to extend life duration assuring a good quality of life; however, further studies are needed to reach these goals.

Original languageEnglish
Pages (from-to)97-104
Number of pages8
JournalCurrent Oncology Reports
Volume14
Issue number2
DOIs
Publication statusPublished - Apr 2012

Fingerprint

Thyroid Neoplasms
Phosphotransferases
Vascular Endothelial Growth Factor Receptor
Factor IX
Therapeutics
Quality of Life
Cell Proliferation
Clinical Trials
Incidence
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • Medullary thyroidcancer
  • Papillary thyroid cancer
  • RET. VEGFR
  • Targeted molecular therapies
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology

Cite this

Antonelli, A., Fallahi, P., Ferrari, S. M., Mancusi, C., Colaci, M., Santarpia, L., & Ferri, C. (2012). RET TKI: Potential role in thyroid cancers. Current Oncology Reports, 14(2), 97-104. https://doi.org/10.1007/s11912-012-0217-0

RET TKI : Potential role in thyroid cancers. / Antonelli, Alessandro; Fallahi, Poupak; Ferrari, Silvia Martina; Mancusi, Caterina; Colaci, Michele; Santarpia, Libero; Ferri, Clodoveo.

In: Current Oncology Reports, Vol. 14, No. 2, 04.2012, p. 97-104.

Research output: Contribution to journalArticle

Antonelli, A, Fallahi, P, Ferrari, SM, Mancusi, C, Colaci, M, Santarpia, L & Ferri, C 2012, 'RET TKI: Potential role in thyroid cancers', Current Oncology Reports, vol. 14, no. 2, pp. 97-104. https://doi.org/10.1007/s11912-012-0217-0
Antonelli A, Fallahi P, Ferrari SM, Mancusi C, Colaci M, Santarpia L et al. RET TKI: Potential role in thyroid cancers. Current Oncology Reports. 2012 Apr;14(2):97-104. https://doi.org/10.1007/s11912-012-0217-0
Antonelli, Alessandro ; Fallahi, Poupak ; Ferrari, Silvia Martina ; Mancusi, Caterina ; Colaci, Michele ; Santarpia, Libero ; Ferri, Clodoveo. / RET TKI : Potential role in thyroid cancers. In: Current Oncology Reports. 2012 ; Vol. 14, No. 2. pp. 97-104.
@article{2a2f4d3b8cc1423db06848297f5c091b,
title = "RET TKI: Potential role in thyroid cancers",
abstract = "The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (RET/PTC) or signaling kinases (vascular endothelial growth factor receptor [VEGFR]) involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies able to inhibit RET (sorafenib, imatinib, vandetanib) in stabilizing the course of the disease. The aim of the introduction of these targeted therapies is to extend life duration assuring a good quality of life; however, further studies are needed to reach these goals.",
keywords = "Medullary thyroidcancer, Papillary thyroid cancer, RET. VEGFR, Targeted molecular therapies, Tyrosine kinase inhibitors",
author = "Alessandro Antonelli and Poupak Fallahi and Ferrari, {Silvia Martina} and Caterina Mancusi and Michele Colaci and Libero Santarpia and Clodoveo Ferri",
year = "2012",
month = "4",
doi = "10.1007/s11912-012-0217-0",
language = "English",
volume = "14",
pages = "97--104",
journal = "Current Oncology Reports",
issn = "1523-3790",
publisher = "Current Science, Inc.",
number = "2",

}

TY - JOUR

T1 - RET TKI

T2 - Potential role in thyroid cancers

AU - Antonelli, Alessandro

AU - Fallahi, Poupak

AU - Ferrari, Silvia Martina

AU - Mancusi, Caterina

AU - Colaci, Michele

AU - Santarpia, Libero

AU - Ferri, Clodoveo

PY - 2012/4

Y1 - 2012/4

N2 - The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (RET/PTC) or signaling kinases (vascular endothelial growth factor receptor [VEGFR]) involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies able to inhibit RET (sorafenib, imatinib, vandetanib) in stabilizing the course of the disease. The aim of the introduction of these targeted therapies is to extend life duration assuring a good quality of life; however, further studies are needed to reach these goals.

AB - The increasing incidence of thyroid cancer is associated with a higher number of advanced disease characterized by the loss of cancer differentiation and metastatic spread. The knowledge of the molecular pathways involved in the pathogenesis of thyroid cancer has made possible the development of new therapeutic drugs able to blockade the oncogenic kinases (RET/PTC) or signaling kinases (vascular endothelial growth factor receptor [VEGFR]) involved in cellular growth and proliferation. Some clinical trials have been conducted showing the ability of targeted therapies able to inhibit RET (sorafenib, imatinib, vandetanib) in stabilizing the course of the disease. The aim of the introduction of these targeted therapies is to extend life duration assuring a good quality of life; however, further studies are needed to reach these goals.

KW - Medullary thyroidcancer

KW - Papillary thyroid cancer

KW - RET. VEGFR

KW - Targeted molecular therapies

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84860869077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860869077&partnerID=8YFLogxK

U2 - 10.1007/s11912-012-0217-0

DO - 10.1007/s11912-012-0217-0

M3 - Article

VL - 14

SP - 97

EP - 104

JO - Current Oncology Reports

JF - Current Oncology Reports

SN - 1523-3790

IS - 2

ER -